Trial site
Katholisches Krankenhaus Hagen gGmbH
Hagen, 58097, GermanyNot linked to an institution yet
- 8running trials
- 2closed trials
The trials here
What the 10 trials at this site are about, from their registry records.
- Phase
- Phase 36 trials
- Phase 21 trial
- Phase 2/31 trial
- Status
- Recruiting5 trials
- Active, not recruiting3 trials
- Completed2 trials
- Lead sponsor
- University of Heidelberg Medical Center3 trials
- Goethe University2 trials
- BioNTech SE1 trial
- Jena University Hospital1 trial
- Klinikum der Universitaet Muenchen AöR1 trial
- and 2 more
Running trials
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma (GMMG-HD9/DSMM XVIII-trial)
2023-507402-13-00· Phase 3· Universitaetsklinikum Heidelberg AöR· Source
Recruiting
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· Phase 2· Goethe University· Source
Active, not recruiting
Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy - DECIDER-2 trial
2023-507461-26-00· Phase 3· Medical Center - University Of Freiburg· Source
Recruiting
ITP Registry and Accompanying Biospecimen Collection
NCT05152238· Jena University Hospital· Source
Contact: Doris Kraemer, Prof. Dr.
Active, not recruiting
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
NCT04534205· Phase 2/3· BioNTech SE· Source
Active, not recruiting
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
NCT03617731· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
NCT02872987· Goethe University· Source
Contact: Nicola Gökbuget, Dr. med.
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error